138682-99-2

Basic information

• Product Name: methyl 2-(3-(hydroxy-phenyl-methyl)-phenyl)-propionate
• Synonyms: methyl 2-(3-(hydroxy-phenyl-methyl)-phenyl)-propionate
• CAS NO: 138682-99-2
• Molecular Weight: 270.328
• Mol File: 138682-99-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl 2-(3-(hydroxy-phenyl-methyl)-phenyl)-propionate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(3-(hydroxy-phenyl-methyl)-phenyl)-propionate(138682-99-2)
• EPA Substance Registry System: methyl 2-(3-(hydroxy-phenyl-methyl)-phenyl)-propionate(138682-99-2)

Safety Data

• Hazardous Substances Data: 138682-99-2(Hazardous Substances Data)

Upstream product

• 22071-15-4 ketoprofen 
• 57872-48-7 ketoprofen methyl ester 

Downstream Products

• 138683-00-8 methyl 2-[3-(phenylchloromethyl)phenyl]propionate 
• 59960-32-6 Dihydroketoprofen 
• 177414-37-8 2-[3-(Amino-phenyl-methyl)-phenyl]-propionic acid methyl ester 
• 177414-33-4 2-[3-(Azido-phenyl-methyl)-phenyl]-propionic acid methyl ester 
• 177414-41-4 2-{3-[(4-Chloro-benzenesulfonylamino)-phenyl-methyl]-phenyl}-propionic acid methyl ester 

Relevant articles and documents

2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors

The CXC chemokine CXCL8/IL-8 plays a major role in the activation and recruitment of polymorphonuclear (PMN) cells at inflammatory sites. CXCL8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCLS-induced human PMNs chemotaxis. We report here molecular modeling studies showing a putative interaction site of 1 in the TM region of CXCR1. The binding model was confirmed by alanine scanning mutagenesis and photoaffinity labeling experiments. The molecular model driven medicinal chemistry optimization of 1 led to a new class of potent and specific inhibitors of CXCL8 biological activity. Among these, repertaxin (13) was selected as a clinical candidate drug for prevention of post-ischemia reperfusion injury.

Intermediates and their use in the preparation of s-ketoprofen

The present invention relates to novel 2-arylpropenoic acids, derivatives thereof, processes for their preparation and their use in the preparation of S-ketoprofen.